FDA Brief

Warning letters Drugs

FDA warning letter to

Harbin Jixianglong Biotech Co., Ltd.

High riskIssued May 1Posted May 19Center for Drug Evaluation and Research (CDER)

FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

What happened

FDA inspected the facility from November 3 to 7, 2025, and found CGMP deviations for active pharmaceutical ingredients (APIs). The company repackaged and relabeled semaglutide bought from suppliers not on its approved list, changed manufacturing and retest dates, named itself as manufacturer, and shipped the API to the U.S. without required drug listing. FDA also found missing process validation, inadequate cleaning validation, incomplete analytical method validation, and water-monitoring gaps; the company later recalled two semaglutide API batches.

What FDA found

  1. The quality unit lacked procedures and oversight for repackaging and relabeling externally bought APIs, and semaglutide from unapproved suppliers was relabeled with new batch numbers and changed dates.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. The company released and distributed semaglutide API to the U.S. without having conducted process validation.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. Cleaning validation was inadequate because the company did not set a maximum carryover limit, justify swab locations, or provide swab test results.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  4. Analytical test methods were not fully validated or verified before tirzepatide API was shipped, and some method validation data were inadequate.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  5. Water used in manufacturing was not adequately monitored and controlled for total microbial counts, objectionable organisms, and endotoxins.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  6. The company failed to list relabeled semaglutide and falsely labeled itself as manufacturer instead of the actual manufacturers.

    FD&C Act sections 510(j), 502(a), 502(b)(1), and 502(o); 21 CFR Part 207

What FDA wants

FDA asks the company to provide risk assessments, CAPA plans, process and cleaning validation, analytical method validation, water-system monitoring, stability data, and customer notification and recall determinations. The provided letter does not state a response deadline.

Who should pay attention

  • U.S. compounding pharmacies and clinics buying GLP-1 APIs
  • brands and distributors sourcing semaglutide or tirzepatide API overseas
  • supplier quality teams managing API repackagers and relabelers

This is a summary. Read the original letter on fda.gov.

Harbin Jixianglong Biotech Co., Ltd.'s FDA history

Recalls in the last 12 months

Mar 11 Class II Harbin Jixianglong Biotech Co., Ltd.
Drug
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer…
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Mar 11 Class II Harbin Jixianglong Biotech Co., Ltd.
Drug
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotec…
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk